Navigation Links
Cytopia Letter to Progen Shareholders
Date:2/25/2009

MELBOURNE, Australia, Feb. 25 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has today circulated a letter and other materials to Progen Pharmaceuticals Limited (ASX: PGL) shareholders. The letter provides an update on the current shareholders requisitioned meeting scheduled for 27 March 2009 and provides recommendations on how to vote at the upcoming general meeting on 11 March 2009.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090225/NY75105)

The letter and the sample proxy form are attached to this release.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase I and Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.

Website: www.cytopia.com.au

Dear Progen shareholder

In the 2007 financial year your company raised nearly $100 million for Phase III trials of PI-88. Since that time:

  • The board terminated the PI-88 Phase III study in liver cancer in July 2008;
  • The share price has fallen from $9.49 in April 2007 to around $0.82, below cash
    '/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cytopia and Other Progen Shareholders Maintain Call for Meeting
2. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
3. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
4. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
5. FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
8. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
9. Stanford writes in worlds smallest letters
10. BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter
11. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2
... to produce methyl ethyl ketone from renewable feedstocks ... Researchers at Genomatica, Inc., a sustainable chemical company, ... ketone (MEK), a commonly used industrial solvent with ... billion. The rapid development breakthrough demonstrates that ...
... Starting with the tiny fruit fly, and then moving into ... Center for Human Genetics (K.U. Leuven) showed that the same ... gene leads to cancer. The scientists think there is a ... with a drug. They report their findings in the reputed ...
... Calif., Feb. 24 Nektar Therapeutics,(Nasdaq: ... the fourth quarter and,year ended December 31, 2008. ... transformational year for Nektar," said Howard W. Robin,President ... our unique polymer,conjugation chemistry platform, we advanced numerous ...
Cached Biology Technology:New Genomatica Chemical Process Targets Ailing Ethanol Assets 2New Genomatica Chemical Process Targets Ailing Ethanol Assets 3New Genomatica Chemical Process Targets Ailing Ethanol Assets 4New Genomatica Chemical Process Targets Ailing Ethanol Assets 5Anti-cancer gene discovered: Perspective for therapy 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... inflammation is a major factor in a wide range of ... fish oil) is known to temper this problem. A new ... The FASEB Journal , helps explain why DHA ... to finding new drugs that will help bring people back ...
... Shenzhen, China The Asian Cancer Research Group (ACRG), ... world,s largest genomics organization, and The University of Hong ... a study of recurrent mutations in hepatocellular carcinoma (HCC), ... international journal Genome Research . The study provides ...
... can have too much of a good thing when it ... to an article published in the July 2013 issue of ... healing can be delayed because the body produces too many ... cells, however, also causes harm by leading to the overproduction ...
Cached Biology News:Harvard and USC scientists show how DHA resolves inflammation 2ACRG and BGI report new evidence for the genetic bases of liver cancer 2Too much of a good thing? Too many 'healing' cells delays wound healing 2
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
Biology Products: